Anti-MOG associated encephalomyelitis

Anti-MOG Associated Encephalomyelitis

Anti-MOG associated encephalomyelitis is a neurological disorder characterized by inflammation of the central nervous system (CNS) due to the presence of antibodies against myelin oligodendrocyte glycoprotein (MOG). This condition is part of a spectrum of demyelinating diseases that affect the brain, spinal cord, and optic nerves.

Pathophysiology

Myelin oligodendrocyte glycoprotein (MOG) is a protein located on the surface of myelin sheaths in the CNS. It plays a crucial role in maintaining the integrity of myelin and facilitating nerve conduction. In anti-MOG associated encephalomyelitis, the immune system mistakenly targets MOG, leading to inflammation and demyelination.

The presence of anti-MOG antibodies is a hallmark of this condition. These antibodies are believed to initiate an immune response that damages myelin, resulting in neurological symptoms.

Clinical Presentation

Patients with anti-MOG associated encephalomyelitis may present with a variety of symptoms, depending on the areas of the CNS affected. Common symptoms include:

• Optic neuritis: Inflammation of the optic nerve, leading to vision loss or impairment.
• Transverse myelitis: Inflammation of the spinal cord, causing weakness, sensory disturbances, and bladder dysfunction.
• Acute disseminated encephalomyelitis (ADEM): A widespread attack of inflammation in the brain and spinal cord, often following an infection or vaccination.

Diagnosis

The diagnosis of anti-MOG associated encephalomyelitis involves a combination of clinical evaluation, imaging studies, and laboratory tests. Key diagnostic tools include:

• Magnetic Resonance Imaging (MRI): To identify areas of inflammation and demyelination in the CNS.
• Serological tests: Detection of anti-MOG antibodies in the blood or cerebrospinal fluid (CSF).

Treatment

Treatment strategies for anti-MOG associated encephalomyelitis focus on reducing inflammation and managing symptoms. Common treatments include:

• Corticosteroids: To reduce acute inflammation.
• Plasma exchange: To remove circulating antibodies from the blood.
• Immunosuppressive therapies: Such as azathioprine or mycophenolate mofetil, to prevent relapses.

Prognosis

The prognosis for patients with anti-MOG associated encephalomyelitis varies. Some individuals experience a monophasic illness with complete recovery, while others may have recurrent episodes. Early diagnosis and treatment are crucial for improving outcomes.

Also see

• Multiple Sclerosis
• Neuromyelitis Optica
• Acute Disseminated Encephalomyelitis
• Transverse Myelitis

edit 

WikiMD neurology

External links

• Comprehensive information from the National Institute of health.
  

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z